Ra Pharma


    Our goal is to become a leading biopharmaceutical company transforming the lives of patients with life-threatening complement-mediated diseases by combining our insights into complement with our leadership in macrocycle chemistry technology.

    Ra Pharma® has leveraged the Extreme Diversity™ platform to rapidly develop a portfolio of products that selectively inhibit the complement system and other immune targets, including its lead program zilucoplan (RA101495 SC). Ra Pharma’s transformational technology can provide products to replace injectable biologics for a range of common and rare diseases.

    Focus and Stage